FDA Approves EXKIVITY (Mobocertinib) for the Treatment of Adult Patients with Locally Advanced or Metastatic NSCLC with EGFR Exon 20 Insertion Mutations Whose Disease Has Progressed on or After Platinum-Based Chemotherapy

label